## Theoretical Analysis: C1q-Driven Synaptic Pruning in Alzheimer's Disease
### Key Molecular Mechanisms
C1q initiates the classical complement cascade, binding directly to synapses in an activity-independent manner—distinct from developmental pruning, which selectively eliminates less-active terminals. This pathway operates through sequential molecular events:
1. **C1q deposition**: Upregulated by astrocytes and neurons in AD brain, binding exposed phosphatidylserine on stressed synapses (Hong et al. 2016, PMID 27339137)
2. **C3 convertase formation**: C1q triggers C4/C2 cleavage, generating C3b opsonin
3. **CR3 (CD11b/CD18) engagement**: Microglial CR3 recognizes C3b-coated synapses, triggering phagocytosis via DAP12/Syk signaling
4. **Synaptic elimination**: Results in progressive synapse loss measurable as dendritic spine reduction before amyloid plaque deposition
The mechanism is compelling because it explains how Aβ oligomers may act upstream—soluble Aβ42 induces C1q binding to synapses (Stephan et al. 2013, PMID 23499003), linking amyloid toxicity to complement-mediated synaptic stripping.
### Testable Predictions
**Prediction 1**: CR3 blockade (e.g., anti-CD11b antibody) in 5xFAD mice at 3 months will preserve hippocampal synapse density and reverse working memory deficits without affecting amyloid plaque load.
**Prediction 2**: C1q-deficient 5xFAD mice will demonstrate intact spatial memory at 6 months despite equivalent plaque burden, with rescued excitatory synaptic transmission in CA1 neurons.
**Prediction 3**: In human AD CSF, the C1q:synapse ratio (measured via proximity ligation assay) will correlate inversely with cognitive performance independent of Aβ42/tau levels.
### Pathway Connections
This mechanism intersects with multiple AD-relevant pathways: microglial dysregulation (TYROBP/DAP12 network), astrocyte reactivity (IL-1β/C1q induction), and mitochondrial dysfunction in neurons creating phosphatidylserine exposure. The complement-synapse interface represents a convergent vulnerability point, explaining why diverse AD genetic risk factors (TREM2, INPP5D, CLU) converge on microglial function.
**Clinical relevance**: ANX005 (C1q antibody) and BRON-N102 (CR3 antagonist) in development directly test this hypothesis; early trial results will be critical.